Urovant Sciences (Urovant Sciences) 6-1 Month Momentum % : 75.95% (As of May. 06, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Urovant Sciences 6-1 Month Momentum %?

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-05-06), Urovant Sciences's 6-1 Month Momentum % is 75.95%.

The industry rank for Urovant Sciences's 6-1 Month Momentum % or its related term are showing as below:

UROV's 6-1 Month Momentum % is not ranked
in the Biotechnology industry.
Industry Median: 0.17 vs UROV: 75.95

Competitive Comparison of Urovant Sciences's 6-1 Month Momentum %

For the Biotechnology subindustry, Urovant Sciences's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Urovant Sciences's 6-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Urovant Sciences's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Urovant Sciences's 6-1 Month Momentum % falls into.

Urovant Sciences (NAS:UROV) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %

( Price 1-month ago

Price 6-month ago

- 1 )

100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Urovant Sciences (NAS:UROV) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Urovant Sciences 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Urovant Sciences's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.

Urovant Sciences (Urovant Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Urovant Sciences Ltd (NAS:UROV) » Definitions » 6-1 Month Momentum %

Comparable Companies

Traded in Other Exchanges

N/A

Address

11-12 St. Jamesâ€™s Square, Suite 1, 3rd Floor, London, GBR, SW1Y 4LB

Website

https://www.urovant.com

Urovant Sciences Ltd is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing therapies for urologic conditions. The company's pipeline products include Overactive Bladder (OAB), OAB in Men with Benign Prostatic Hyperplasia (BPH), and IBS-Associated Pain.

Executives

Myrtle S Potter	director	10 FINDERNE AVE, BRIDGEWATER NJ 08807
Sef Kurstjens	director	C/O UROVANT SCIENCES, INC. 5281 CALIFORNIA AVENUE, SUITE 100 IRVINE CA 92617
Pierre Legault	director	P.O. BOX 1028, C/O STONE MANAGEMENT LLC, BERWYNE PA 19312
James M. Hindman	director	2525 DUPONT DRIVE, IRVINE CA 92612
Walt Johnston	officer: SVP, Commercial, USI	UROVANT SCIENCES LTD. 5281 CALIFORNIA AVE SUITE 100 IRVINE CA 92617
Haag-molkenteller Cornelia	officer: CMO/Urovant Sciences, Inc.	C/O UROVANT SCIENCES, INC. 5281 CALIFORNIA AVENUE, SUITE 100 IRVINE CA 92617
Bryan E. Smith	officer: GC/Urovant Sciences, Inc.	C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617
Christine Ocampo	officer: PAO;CAO/Urovant Sciences, Inc	C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617
Ajay Bansal	officer: PFO;CFO/Urovant Sciences, Inc.	C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617
Robinson James A. Jr.	director, officer: PEO;CEO/Urovant Sciences, Inc.	852 WINTER STREET, WALTHAM MA 02451
Sumitomo Chemical Co., Ltd.	other: See Footnote (1)	7-1, NIHONBASHI 2-CHOME, CHUO-KU, TOKYO M0 103-6020
Sumitovant Biopharma Ltd.	10 percent owner	C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Dainippon Sumitomo Pharma Co Ltd	other: See Footnote (1)	6-8 DOSHOMACHI 2-CHOME, CHUO-KU, OSAKA M0 541-0045
Keith Katkin	director, officer: PEO;CEO/Urovant Sciences, Inc.	C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617
Shigeyuki Nishinaka	director	5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617